BD LSR II Flow Cytometer

描述（由申请人提供）：在芝加哥大学，多参数流式细胞术已被证明是许多生物和医学研究领域不可或缺的工具。以精确和快速的方式识别和枚举单个活细胞的能力使得从任何数量的组织和器官中鉴定稀有细胞类型成为可能。检测此类事件的能力对于癌症和免疫介导疾病的研究尤为重要。以前，多参数流式细胞仪已经能够识别许多这样的细胞类型；然而，许多商用仪器已经达到了荧光检测的极限。在干细胞研究和造血领域，解决抗原表达非常低的细胞类型的必要性已经变得很明显。因此，很明显，能够以高通量率同时检测多个参数的仪器，并解决这些模糊荧光细胞亚型，对于芝加哥大学研究的持续发展是必要的。一种新的，高灵敏度，4激光，14参数BD LSRII将允许这些检测标准，也减轻了用户目前遇到的一些容量问题。由于现有设施的LSRII使用率增加了15%，并且Cyan-ADP的损失迫使该设施开始租赁所需的LSRII。因此，已对该提案进行了修订，要求出资买断租用的仪器，以便主要调查人员可以继续进行研究。12个主要用户与许多NIH资助的项目专注于各种生物医学科学，包括造血、哮喘、宿主防御、肺损伤、移植、自身免疫性疾病以及基础癌症和免疫学研究，将依赖于该仪器。该仪器将被安置在芝加哥大学的校园流式细胞仪核心设施，这将有助于提高使用效率。通过将该仪器放置在校园内已经建立的核心设施中（服务于bbb80 PI），教师将能够利用设施主管和工作人员在操作和使用方面的专业知识。此外，在核心设施中，向所有大学调查员提供平等的访问机会。因此，该仪器将极大地有利于芝加哥大学缓解目前的能力问题，并提供最先进的技术，使我们的研究人员保持在他们的研究的最前沿。公共卫生相关性：12个NIH资助的生物医学研究领域的项目，如造血、哮喘、宿主防御、肺损伤、移植、自身免疫性疾病、癌症和免疫学机制，将严重依赖所要求的仪器。所要求的仪器所采用的最先进技术将有助于揭示回答这些重要问题所需的信息。

DESCRIPTION (provided by applicant): Multiparametric flow cytometry has proven to be an indispensable tool for numerous areas of biological and medical research at the University of Chicago. The ability to identify and enumerate individual living cells in a precise and rapid fashion has allowed for the characterization of rare cell types from any number of tissues and organs. The ability to detect such events is particularly crucial for the study of cancer and immune-mediated diseases. Previously, multiparametric flow cytometers have been able to identify many such cell types; however the limits of fluorescence detection have been reached on many commercial instruments. The necessity to resolve cell types with very low antigen expression has become evident in the area of stem cell research and hematopoiesis. Therefore, it is evident that instrumentation that will be able to detect multiple parameters simultaneously at high through-put rates, and also resolve these dimly fluorescent cell subtypes, is necessary for the continued advancement of the research at the University of Chicago. A new, high sensitivity, 4-laser, 14-parameter BD LSRII will allow for these detection criterion, and also alleviate some of the capacity issues currently experienced by the user base. A 15% increase in usage of the current facility's LSRII and the loss of the Cyan-ADP has forced the facility to begin leasing the requested LSRII. As such this proposal has been revised to request funding to buyout the leased instrument so that the major investigators may continue to perform their studies. Twelve major users with as many NIH funded projects focusing on a wide variety of biomedical science including hematopoiesis, asthma, host defense, lung injury, transplantation, autoimmune diseases as well as basic cancer and immunology research, will depend on this instrumentation. The efficiency of the usage of this instrument will be aided by its placement in the University of Chicago Flow Cytometry Core Facility on campus. By placing this instrument in the already established core facility on campus (serving >80 PI's), the faculty will be able to exploit the expert knowledge of the facility directors and staff in its operation and usage. Further, in the core facility equal access is provided to all University Investigators. Thus, this instrument will greatly benefit the University of Chicago by easing current capacity issues and providing state-of-the-art technology, allowing our investigators to remain at the forefront of their research. PUBLIC HEALTH RELEVANCE: Twelve NIH funded projects focusing on biomedical research areas such as hematopoiesis, asthma, host defense, lung injury, transplantation, autoimmune diseases, mechanisms of cancer and immunology will rely heavily on the requested instrumentation. State-of-the-art technologies employed on the requested instrument will help unveil the information necessary to answer these important questions.